Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Sexual Dysfunctions, Psychological 1Breast Neoplasms 1

Interventions

pembrolizumab 31Carboplatin 24Specimen Handling 19Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Nivolumab 14Dexamethasone 14Bevacizumab 13fludarabine 12atezolizumab 11Temozolomide 11Gemcitabine 11Biopsy 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Cisplatin 8Rituximab 7Prednisone 7Oxaliplatin 7Lenalidomide 7Fluorouracil 7Docetaxel 7Capecitabine 7olaparib 6Vincristine 6Leucovorin 6patritumab deruxtecan 5lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leuprolide × 30 days × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡